Results 31 to 40 of about 176,389 (357)

Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment

International Journal of Molecular Sciences, 2022
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease, affecting approximately one-quarter of the global population, and has become a world public health issue.
Xiangyu Guo, Xunzhe Yin, Zuo-Jia Liu, Jin Wang   +3 more
semanticscholar   +1 more source

Sympathetic Nervous System Catecholamines and Neuropeptide Y Neurotransmitters Are Upregulated in Human NAFLD and Modulate the Fibrogenic Function of Hepatic Stellate Cells [PDF]

, 2013
Background Sympathetic nervous system (SNS) signalling regulates murine hepatic fibrogenesis through effects on hepatic stellate cells (HSC), and obesity-related hypertension with SNS activation accelerates progression of non-alcoholic fatty liver ...
Vander Borght, S, McKee, C, Vander Borght Sara, Mazzoccoli, G, Ching-I Lin, Gianluigi Mazzoccoli, Lin Ching-I, Selden, C, Maelle Morgan, Pazienza Valerio, Selden Clare, Junpei Soeda, Jude A Oben, Barbara Sigala, Manlio Vinciguerra, Oben, JA, Tania Roskams, Sara Vander Borght, Pazienza, V, Roskams, T, Clare Selden, Lin, CI, McKee Chad, Mazzoccoli Gianluigi, Vinciguerra, M, Morgan Maelle, Valerio Pazienza, Sigala Barbara, Vinciguerra Manlio, Soeda, J, Chad McKee, Soeda Junpei, Oben Jude A., Sigala, B, Roskams Tania, Morgan, M   +35 more
core   +2 more sources

Intestinal peroxisome proliferator‐activated receptor α‐fatty acid‐binding protein 1 axis modulates nonalcoholic steatohepatitis

Hepatology, EarlyView., 2022
Abstract Background and Aims Peroxisome proliferator‐activated receptor α (PPARα) regulates fatty acid transport and catabolism in liver. However, the role of intestinal PPARα in lipid homeostasis is largely unknown. Here, intestinal PPARα was examined for its modulation of obesity and NASH. Approach and Results Intestinal PPARα was activated and fatty
Tingting Yan, Yuhong Luo, Nana Yan, Keisuke Hamada, Nan Zhao, Yangliu Xia, Ping Wang, Changdong Zhao, Dan Qi, Shoumei Yang, Lulu Sun, Jie Cai, Qiong Wang, Changtao Jiang, Oksana Gavrilova, Kristopher W. Krausz, Daxesh P. Patel, Xiaoting Yu, Xuan Wu, Haiping Hao, Weiwei Liu, Aijuan Qu, Frank J. Gonzalez   +22 more
wiley   +1 more source

MAFLD: How is it different from NAFLD?

Clinical and Molecular Hepatology, 2022
“Metabolic dysfunction-associated fatty liver disease (MAFLD)” is the term suggested in 2020 to refer to fatty liver disease related to systemic metabolic dysregulation.
C. Gofton, Yadhavan Upendran, M. Zheng, Jacob George   +3 more
semanticscholar   +1 more source

Insulin sensitisers in the treatment of non-alcoholic fatty liver disease : a systematic review [PDF]

, 2011
Non-alcoholic fatty liver disease (NAFLD) is closely linked with obesity and the prevalence of NAFLD is about 17% to 33% in the Western world. There is a strong association of NAFLD with insulin resistance and, hence, insulin sensitisers have been tried.
C Clar, Henderson, R., Gurung, T., N Waugh, N Sattar, N Ghouri, Clar, C., Sattar, Naveed, Sattar, N., Fraser, A., T Gurung, Gurung, T. (Tara), D Shyangdan, A Fraser, Shyangdan, D., D Preiss, Waugh, Norman, Shyangdan, D. (Deepson), R Henderson, Ghouri, N., Preiss, D., Waugh, N.   +21 more
core   +1 more source

NAFLD‐related hepatocellular carcinoma: The growing challenge

Hepatology, EarlyView., 2022
Risk and protective factors for NAFLD‐related hepatocellular carcinoma Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially.
Pir Ahmad Shah, Rashmee Patil, Stephen A. Harrison   +2 more
wiley   +1 more source

Mechanisms of NAFLD development and therapeutic strategies

Nature Medicine, 2018
There has been a rise in the prevalence of nonalcoholic fatty liver disease (NAFLD), paralleling a worldwide increase in diabetes and metabolic syndrome.
S. Friedman, B. Neuschwander‐Tetri, M. Rinella, A. Sanyal   +3 more
semanticscholar   +1 more source

AGA Clinical Practice Update: Diagnosis and Management of Non-Alcoholic Fatty Liver Disease (NAFLD) in Lean Individuals: Expert Review

Gastroenterology, 2022
Nonalcoholic fatty liver disease (NAFLD) is well-recognized as a leading etiology for chronic liver disease, affecting over 25% of the U.S. and global population. Up to one in four individuals with NAFLD have nonalcoholic steatohepatitis (NASH), which is
Michelle T. Long, M. Noureddin, Joseph K. Lim   +2 more
semanticscholar   +1 more source

Lipocalin‐2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high‐fat diet–fed Ob/Ob mice

Hepatology, EarlyView., 2022
Graphical summary of obesity‐induced NASH progression by LCN2 targeted to HSC activation. Abstract Background and Aims In obesity and type 2 diabetes mellitus, leptin promotes insulin resistance and contributes to the progression of NASH via activation of hepatic stellate cells (HSCs).
Kyung Eun Kim, Jaewoong Lee, Hyun Joo Shin, Eun Ae Jeong, Hye Min Jang, Yu Jeong Ahn, Hyeong Seok An, Jong Youl Lee, Meong Cheol Shin, Soo Kyoung Kim, Won Gi Yoo, Won Ho Kim, Gu Seob Roh   +12 more
wiley   +1 more source

The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?

, 2021
Background & Aims Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent, yet largely underappreciated liver condition which is closely associated with obesity and metabolic disease.
Consortium, Shawa, I.
core   +2 more sources